Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.80 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.41 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.41 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL14485654 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11SLC7A5ENPEPSLC1A3 | |
| Cysteine SCHEMBL1675939 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11SLC7A5ENPEPSLC1A3 | |
| Cysteine SCHEMBL1675940 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11SLC7A5ENPEPSLC1A3 | |
| Cysteine SCHEMBL23752302 | 0.92 | PTGS1 (0.84) | PTGS1SLC7A11SLC7A5ENPEPSLC1A3 | |
| Cysteine SCHEMBL6515757 | 0.91 | PTGS1 (0.67) | PTGS1SLC7A11SLC7A5ENPEPSLC1A3 | |
| Serine SCHEMBL27493874 | 0.91 | PTGS1 (0.67) | PTGS1SLC7A11SLC7A5ENPEPSLC1A3 | |
| Serine SCHEMBL1018119 | 0.91 | PTGS1 (0.67) | PTGS1SLC7A11SLC7A5ENPEPSLC1A3 | |
| Cysteine SCHEMBL12505856 | 0.91 | PTGS1 (0.67) | PTGS1SLC7A11SLC7A5ENPEPSLC1A3 | |
| Serine SCHEMBL21752129 | 0.91 | PTGS1 (0.67) | PTGS1SLC7A11SLC7A5ENPEPSLC1A3 | |
| Cysteine SCHEMBL17315768 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240075050-A1 | Methods and Compositions for Treating Leucine Rich Repeat Kinase 2 (LRRK2)-Associated Disorder or Condition | UNIVERSITY OF CONNECTICUT (US) | 2024-03-07 | — | — | US | disclosed |
| WO-2024050426-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCERS BY MODULATING THE EXPRESSION AND/OR ACTIVITY OF STUB1 | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20230192839-A1 | ANTIBODIES HAVING CONDITIONAL AFFINITY AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230130858-A1 | TARGET-SPECIFIC CRISPR MUTANT | TOOLGEN INCORPORATED (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20220204955-A1 | TARGET-SPECIFIC CRISPR MUTANT | TOOLGEN INCORPORATED (KR) | 2022-06-30 | — | — | US | disclosed |
| EP-3960853-A1 | TARGET SPECIFIC CRISPR MUTANT | Toolgen Incorporated (KR) | 2022-03-02 | — | — | EP | disclosed |
| US-20210236465-A1 | METHODS AND COMPOSITIONS FOR TREATING HETEROTOPIC OSSIFICATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-05 | — | — | US | disclosed |
| WO-2020218657-A1 | TARGET SPECIFIC CRISPR MUTANT | 주식회사 툴젠 | 2020-10-29 | — | — | WO | disclosed |
| US-20200149022-A1 | TARGET-SPECIFIC CRISPR MUTANT | TOOLGEN INCORPORATED (KR) | 2020-05-14 | — | — | US | disclosed |
| EP-3650540-A2 | TARGET-SPECIFIC CRISPR MUTANT | Toolgen Incorporated (KR) | 2020-05-13 | — | — | EP | disclosed |
| US-20090162372-A1 | FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE | MEDAREX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2009073533-A2 | ANTI-B7H4 MONOCLONAL ANTIBODY-DRUG CONJUGATE AND METHODS OF USE | MEDAREX, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009073524-A2 | CONJUGATES OF ANTI-RG-1 ANTIBODIES | MEDAREX, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009073546-A2 | MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) | MEDAREX, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009054863-A2 | HUMAN ANTIBODIES THAT BIND CD19 AND USES THEREOF | MEDAREX, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009045957-A1 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF | MEDAREX, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2008153926-A2 | INHIBITORS OF RECEPTOR TYROSINE KINASES AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008083312-A2 | CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF | MEDAREX, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008074004-A2 | HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF | MEDAREX, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| CN-1655812-A | Anitmicrobial polymer conjugates | BIOSYNEXUS INC (US) | 2005-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162372-A1 | FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE | FN1, EDNRB, EDF1 | PTGS1 4837/4885SLC7A11 3208/4885SLC7A5 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.